Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-09T15:34:50.787Z Has data issue: false hasContentIssue false
  • English
  • Français

Token Economy, Pimozide and Chronic Schizophrenia

Published online by Cambridge University Press:  29 January 2018

Robin G. McCreadie ,
Christopher J. Main  and
Rosalyn A. Dunlop
Robin G. McCreadie
Affiliation:
Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow, G12 0XH
Christopher J. Main
Affiliation:
Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow, G12 0XH
Rosalyn A. Dunlop
Affiliation:
Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow, G12 0XH
Get access Rights & Permissions [Opens in a new window]

Summary

Response to a token economy was assessed in male chronic schizophrenic in-patients who were given, in a double-blind cross-over trial, pimozide (up to 20 mg daily) or chlorpromazine (up to 1,000 mg daily), each for three months. After six months there was little change in the patients' mental state, but general ward behaviour and token-rewarded target behaviours improved significantly. There were no statistically significant between-drug differences, but the trend was that general ward behaviour, but not token-rewarded behaviour, improved more on pimozide. The patients who showed initiative and cooperated best with staff were those whose token-rewarded behaviour was most satisfactory.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 133 , Issue 2 , August 1978 , pp. 179 - 181
Copyright
Copyright © Royal College of Psychiatrists, 1978 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Hall, J. N. & Baker, R. D. (1973) Token economy systems: breakdown and control. Behaviour Research and Therapy, 11, 253–63.CrossRefGoogle ScholarPubMed
Hall, J. N., Baker, R. D. & Hutchinson, K. (1977) A controlled evaluation of token economy procedures with chronic schizophrenic patients. Behaviour Research and Therapy, 15, 261–83.CrossRefGoogle ScholarPubMed
Hamilton, M., Smith, A. L. G., Lapidus, H. E. & Cadogan, E. P. (1960) A controlled trial of thiopropazate dihydrochloride (Dartalan), chlorpromazine and occupational therapy in chronic schizophrenics. Journal of Mental Science, 106, 40–55.CrossRefGoogle ScholarPubMed
Honigfeld, G. & Klett, C. J. (1965) The Nurses Observation Scale for Inpatient Evaluation. Journal of Clinical Psychology, 21, 65–71.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
Liberman, R. P., Davis, J., Moon, W. & Moore, J. (1973) Research design for analyzing drug-environment-behaviour interactions. Journal of Nervous and Mental Disease, 156, 432–9.CrossRefGoogle ScholarPubMed
McCreadie, R. G. & McDonald, I. M. (1977) High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry, 131, 310–16.CrossRefGoogle ScholarPubMed
Mellor, C. S. (1970) First rank symptoms of schizophrenia. British Journal of Psychiatry, 117, 15–23.CrossRefGoogle ScholarPubMed
Mumford, S. J., Lodgepatch, I. C., Andrews, N. & Wyner, L. (1975) A token economy ward programme with chronic schizophrenic patients. British Journal of Psychiatry, 126, 60–72.CrossRefGoogle ScholarPubMed
Pinder, R. M., Brogden, R. N., Sawyer, P. R., Speight, T. M., Spencer, R. & Avery, G. S. (1976) Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry. Drugs, 12, 1–40.CrossRefGoogle ScholarPubMed
Presly, A. S., Black, D., Gray, A., Hartie, A. & Seymour, E. (1976) The token economy in the National Health Service: possibilities and limitations. Acta Psychiatrica Scandinavica, 53, 258–70.CrossRefGoogle ScholarPubMed
Siegel, S. (1956) Non-parametric Statistics for the Behavioural Sciences. New York: McGraw-Hill.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.